These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 2752254

  • 1. CA-50 as tumour marker in transitional bladder carcinoma.
    Tizzani A, Casetta G, Piana P, Piantino P.
    Br J Urol; 1989 Jun; 63(6):616-8. PubMed ID: 2752254
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Monoclonal antibodies to detect A, B and H blood group isoantigens in superficial transitional cell carcinoma of the bladder: a means of predicting invasive recurrences.
    Stephenson TJ, Williams JL, Gelsthorpe K.
    Br J Urol; 1985 Apr; 57(2):148-53. PubMed ID: 3886066
    [Abstract] [Full Text] [Related]

  • 7. [Studies on multiple mucosal biopsy in patients with bladder cancer. 4. Evaluation of Thomsen-Friedenreich antigen in multiple mucosal biopsy and transitional cell carcinoma of the bladder].
    Igawa M.
    Hinyokika Kiyo; 1986 Nov; 32(11):1663-76. PubMed ID: 3825815
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression of C-50 antigen as a prognostic variable in transitional cell bladder tumours.
    Lipponen PK, Eskelinen MJ.
    Br J Urol; 1993 Feb; 71(2):192-8. PubMed ID: 8461954
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical demonstration of tumor-associated antigens with the aid of monoclonal and polyclonal antisera in carcinoma of the bladder.
    Steffens J, Friedmann W, Lobeck H.
    Urol Res; 1985 Feb; 13(2):55-9. PubMed ID: 2409654
    [Abstract] [Full Text] [Related]

  • 11. Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder.
    Carballido J, Alvarez-Mon M, Solovera OJ, Menéndez-Ondina L, Durántez A.
    J Urol; 1990 Jan; 143(1):29-33. PubMed ID: 2294256
    [Abstract] [Full Text] [Related]

  • 12. [Immunohistochemical determination of antigen 19-9 (CA 19-9) in transitional carcinoma of the bladder].
    Casetta G, Cavallini A, Piana P, Squintone L, Vottero M, Tizzani A.
    Minerva Urol Nefrol; 1992 Jan; 44(3):169-72. PubMed ID: 1492266
    [Abstract] [Full Text] [Related]

  • 13. Changing expression of ABH blood group and cryptic T-antigens of noninvasive and superficially invasive papillary transitional cell carcinoma of the bladder from initial occurrence to malignant progression.
    Yamada T, Fukui I, Yokokawa M, Oshima H.
    Cancer; 1988 Feb 15; 61(4):721-6. PubMed ID: 3338034
    [Abstract] [Full Text] [Related]

  • 14. Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses.
    Pizza G, Viza D, Fini M, Cuzzocrea D, Menniti D, Corrado F.
    Eur Urol; 1980 Feb 15; 6(1):45-7. PubMed ID: 7353578
    [Abstract] [Full Text] [Related]

  • 15. DNA flow cytometry and 67Ki proliferating index as prognostic factors of early recurrence and progression in G1-G2/Ta-T1 and G3/Ta-T1 transitional cell carcinoma of the bladder.
    Tizzani A, Casetta G, Gontero P, Giammò A, Ghabin H, Demurtas S, Pacchioni D.
    Minerva Urol Nefrol; 1997 Sep 15; 49(3):141-3. PubMed ID: 9396221
    [Abstract] [Full Text] [Related]

  • 16. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
    Kouba EJ, Lentz A, Wallen EM, Pruthi RS.
    Urol Oncol; 2009 Sep 15; 27(5):486-90. PubMed ID: 18555706
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer.
    Smith G, Elton RA, Beynon LL, Newsam JE, Chisholm GD, Hargreave TB.
    Br J Urol; 1983 Dec 15; 55(6):665-9. PubMed ID: 6652436
    [Abstract] [Full Text] [Related]

  • 18. Immunologic reduction of bladder cancer recurrence rate.
    Olsson CA, Chute R, Rao CN.
    J Urol; 1974 Feb 15; 111(2):173-6. PubMed ID: 4810758
    [No Abstract] [Full Text] [Related]

  • 19. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J.
    J Urol; 2017 Oct 15; 198(4):817-823. PubMed ID: 28487100
    [Abstract] [Full Text] [Related]

  • 20. Carbohydrate antigen 19-9 and carcinoembryonic antigen-producing transitional cell carcinoma of the ureter and bladder: a case report.
    Sakai H, Toyofuku K, Yogi Y, Minami Y, Kanetake H, Saito Y.
    J Urol; 1993 Jul 15; 150(1):182-4. PubMed ID: 8510248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.